期刊文献+

The Clinical Randomized Controlled Trial on the Safety and Efficacy of Polyethersulfone Membrane Dialyzer in the Maintenance of Hemodialysis Patients

The Clinical Randomized Controlled Trial on the Safety and Efficacy of Polyethersulfone Membrane Dialyzer in the Maintenance of Hemodialysis Patients
下载PDF
导出
摘要 Objective:To observe the safety and efficacy of polyethersulfone membrane dialyzer used by chronic renal failure patients in clinical maintenance hemodialysis(MHD).Methods:From January to February 2009,36 patients were recruited from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.The experiment was approved by the ethnical committee of Xinhua Hospital and under permissions from patients.All the patients were randomized into polyethersulfone group(PES,n=18) and polysulfone group(PS,n=18).Hemodialysis was given by using Fresenius 4008S capacity-controlled dialyser and ultra-purified bicarbonate dialysate,more than 3.5 h each time,three times per-week,followed by heparin anticoagulation for a week,three times totally.Changes in blood urea nitrogen(BUN),serum creatinine(Scr),phosphate(P2+),hemoglobin and albumin levels were determined for the efficacy and safety evaluation.Results:The serum BUN,Scr and P2+ concentrations significantly reduced after hemodialysis with different dialyzers,and the decrease amplitude of two groups was equivalent(P>0.05).The clearance rate of the serum BUN and Scr had no significant difference among two groups(P>0.05).The clearance rate(ml/min) of the serum P2+ was 144.57±27.83 v.s.117.15±22.77 in two groups.The clearance rate of the serum P2+ in PES group was more than that in PS group,and the difference was significant between two groups(P=0.0001).It was indicated that PES and PS membrane could efficiently eliminate serum micromolecule solute in MHD patients,so PES membrane excelled PS membrane in eliminating serum P2+.The hemodialysis safety index,for example serum hemoglobin,albumin and blood pressure,had no significant difference between the two groups before and after hemodialysis(P>0.05).Conclusion:The efficacy and safety of the PES hollow fiber membrane dialyzer is equivalent to that of the imported PS membrane dialyzer in hemodialysis for MHD patients.The PES membrane excels PS membrane in eliminating serum P2+. Objective: To observe the safety and efficacy of polyethersulfone membrane dialyzer used by chronic renal failure patients in clinical maintenance hemodialysis (MHD). Methods: From January to February 2009, 36 patients were recruited from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The experiment was approved by the ethnical committee of Xinhua Hospital and under permissions fronl patients. All the patients were randomized into polyethersulfone group (PES, n=18) and polysulfone group (PS, n=18). Hemodialysis was given by using Fresenius 4008S capacity-controlled dialyser and ultra-purified bicarbonate dialysate, more than 3.5 h each time, three times per-week, followed by heparin anticoagulation for a week, three times totally. Changes in blood urea nitrogen (BUN), serum creatinine (Set), phosphate (p2+), hemoglobin and albumin levels were determined for the efficacy and safety evahlation. Results: The serum BUN, Set and p2+ concentrations significantly reduced after hemodialysis with different dialyzers, and the decrease amplitude of two groups was equivalent(P〉0.05). The clearance rate of the serum BUN and Scr had no significant difference among two groups(P〉O.05). The clearance rate (ml/min) of the sermn P^2+ was 144.57 ±27.83 v.s. 117.15 ±22.77 in two groups. The clearance rate of the serum p^2+ in PES group was more than that in PS group, and the difference was significant between two groups (P=0.0001). It was indicated that PES and PS membrane could efficiently eliminate serum mieromolecule solute in MHD patients, so PES membrane excelled PS membrane in eliminating serum p2+. The hemodialysis safety index, for example serum hemoglobin, albumin and blood pressure, had no significant difference between the two groups before and after hemodialysis (P〉0.05). Conclusion: The efficacy and safety of the PES hollow fiber membrane dialyzer is equivalent to that of the imported PS membrane dialyzer in hemodialysis for MHD patients. The PES membrane excels PS membrane in eliminating sermn p^2+.
出处 《Chinese Journal of Biomedical Engineering(English Edition)》 2010年第4期148-155,共8页 中国生物医学工程学报(英文版)
关键词 HEMODIALYSIS pelyethersulfone dialyzer 使随机化的控制试用 溶质 血磷酸盐 hemodialysis polyethersulfone membrane dialyzer randomizedcontrolled trial solute blood phosphate
  • 相关文献

参考文献5

  • 1王鑫,汪涛.透析患者钙磷代谢紊乱与心血管钙化的研究进展[J].中国血液净化,2002,1(11):39-44. 被引量:13
  • 2Llach F,Yudd M.The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure[].Nephrology Dialysis Transplantation.2006
  • 3Slatopolsky E,Brown A,Dusso A.Role of phosphorus in the pathogenesis of secondary hyperparathyroidism[].American Journal of Kidney Diseases.2001
  • 4Llach F,Massry SG.On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency[].Journal of Clinical Endocrinology and Metabolism.1985
  • 5Krane V,Krieter DH,Olschewski M,et al.Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis[].American Journal of Kidney Diseases.2007

二级参考文献8

  • 1[1]Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease. Am J Kidney Dis, 1998, 32: S112-119
  • 2[2]Block GA, Hulbert-Shearon TE, LevinNW, et al. Association of serum phosphorus and calcium×phosphorus product with mortality risk in chronic hemodialysis patients : a national study . Am J Kidney Dis, 1998, 31: 607-617
  • 3[3]Levin NW, Hulberg-shearron TE, Straderman RL, et al. Which causes of death are related to hyperphosphatemia in hemodialysis patients. J Am Soc Nephrol, 1998, 9: 217A (abstr)
  • 4[4]Rumberger JA, Brundage BH, Rader DJ, et al. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc, 1999, 74: 243-252
  • 5[5]Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. Am J Kidney Dis, 1996, 27: 394-401
  • 6[6]Farzaneh-Far A, Proudfoot D, Shanhan C, et al. Vascular and valvar calcification: recent advances. Heart, 2001, 85: 13-17
  • 7[7]Celilia M, Giachelli, Shuichi Jono. Vascular calcification and inorganic phosphate. Am J Kidney Dis, 2001, suppl 1: S34-S37
  • 8[8]Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis, 2000, 35: 1226-1237

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部